Filing Flows › Bicycle Therapeutics (BCYC) › Q2 2026
Bicycle Therapeutics (BCYC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 30, 2026
Bicycle Therapeutics (BCYC) reported revenue of $629K for the second quarter 2026 (Q2 2026), -78% from a year earlier and -29% from the quarter before.
Bicycle Therapeutics, Q2 2026: revenue $629K (-78% year over year), net loss $50.3M, operating cash flow −$49.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $629K | -29% | -78% |
| Operating profit | −$54.6M | — | — |
| Net earnings | −$50.3M | — | — |
| Operating cash flow | −$49.6M | — | — |
What changed
Revenue was $629K in Q2 2026, down 78% year over year and down 29% from the previous quarter.
Operating costs exceeded revenue by $54.6M, an operating margin of -8673.9%. Total costs fell 38% while revenue fell 78%. The quarter ended with a net loss of $50.3M, narrower than the previous quarter's $60.8M loss.
Operating cash flow was −$49.6M. Non-cash charges added back $1.1M of depreciation and amortization and $6.4M of share-based compensation. Working capital and other items used $6.7M. Capital expenditures of $265K exceeded it, leaving free cash flow of −$49.9M.
Questions
What was Bicycle Therapeutics' revenue in the second quarter 2026?
Bicycle Therapeutics (BCYC) reported revenue of $629K for the second quarter 2026 (Q2 2026), -78% from a year earlier and -29% from the quarter before.